Salus Biomed, a sequencing and spatial omics platform provider based in Guangdong, has reportedly raised over RMB 100 million (USD 13.89 million) in a Pre-Series A financing round. The funding will support regulatory filings and ongoing research and development of its gene sequencing platform and super-resolution spatial omics products, as well as the exploration of other novel products.
Financing Details
The Pre-Series A1 round was led by Shenzhen Qilou Investment Consulting Partnership Limited, while the Pre-Series A2 round was co-led by Qianhai Great Wall Fund. Longing Biotech also contributed to the second funding round. The proceeds will be used to advance Salus Biomed’s core sequencing technology and expand its product offerings.
Company Background and Innovation
Founded in 2020, Salus Biomed has achieved innovation and iteration in various fields, including surface chemistry, sequencing enzymes, optical modules, and data analysis. These advancements are driven by the company’s in-house developed sequencing technology, which serves as the core of its overall design and core module optimization.
Future Outlook
The successful financing round underscores Salus Biomed’s commitment to advancing its gene sequencing platform and super-resolution spatial omics products. By leveraging the latest funding, the company aims to enhance its technological capabilities and expand its market presence in the rapidly growing field of genomics.-Fineline Info & Tech
